Prognostic Value of Metabolism-Related Genes and Immune Infiltration in Clear Cell Renal Cell Carcinoma

References

• Deveson Kell S. Renal cell carcinoma: treatment options. Br J Nurs. 2011;20(9):536, 538–539.
   PubMedGoogle Scholar
• Shuch B, Amin A, Armstrong AJ, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2015;67(1):85–97. doi:10.1016/j.eururo.2014.04.029
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):17009. doi:10.1038/nrdp.2017.9
   PubMed Web of Science ®Google Scholar
• Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23(1):18–25. doi:10.1016/j.semcancer.2012.06.001
   PubMed Web of Science ®Google Scholar
• Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017;13(7):410–419. doi:10.1038/nrneph.2017.59
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–1132. doi:10.1016/S0140-6736(09)60229-4
   PubMed Web of Science ®Google Scholar
• Battaglia M, Lucarelli G. The role of renal surgery in the era of targeted therapy: the urologist’s perspective. Urologia. 2015;82(3):137–138. doi:10.5301/uro.5000105
   PubMedGoogle Scholar
• Di Lorenzo G, De Placido S, Pagliuca M, et al. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opin Biol Ther. 2016;16(11):1387–1401. doi:10.1080/14712598.2016.1216964
   PubMed Web of Science ®Google Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349(nov10 11):g4797. doi:10.1136/bmj.g4797
   PubMed Web of Science ®Google Scholar
• Tamma R, Rutigliano M, Lucarelli G, et al. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019;37(6):355e311–355 e319. doi:10.1016/j.urolonc.2019.01.025
   Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Longo DL. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–366. doi:10.1056/NEJMra1601333
   PubMed Web of Science ®Google Scholar
• Courtney KD, Infante JR, Lam ET, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2 alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol. 2018;36(9):867–874. doi:10.1200/JCO.2017.74.2627
   PubMed Web of Science ®Google Scholar
• Rao S, Mondragon L, Pranjic B, et al. AIF-regulated oxidative phosphorylation supports lung cancer development. Cell Res. 2019;29(7):579–591. doi:10.1038/s41422-019-0181-4
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature12222
   PubMed Web of Science ®Google Scholar
• Ricketts CJ, De Cubas AA, Fan H, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313–326 e315.
   PubMed Web of Science ®Google Scholar
• Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45(8):860–867. doi:10.1038/ng.2699
   PubMed Web of Science ®Google Scholar
• Valera VA, Merino MJ. Misdiagnosis of clear cell renal cell carcinoma. Nat Rev Urol. 2011;8(6):321–333. doi:10.1038/nrurol.2011.64
   PubMed Web of Science ®Google Scholar
• Xie C, Ji N, Tang Z, Li J, Chen Q. The role of extracellular vesicles from different origin in the microenvironment of head and neck cancers. Mol Cancer. 2019;18(1):83. doi:10.1186/s12943-019-0985-3
   PubMed Web of Science ®Google Scholar
• Vuong L, Kotecha RR, Voss MH, Hakimi AA. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019;9(10):1349–1357. doi:10.1158/2159-8290.CD-19-0499
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828–1837. doi:10.1056/NEJMoa032520
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011;481(7381):385–388. doi:10.1038/nature10642
   PubMed Web of Science ®Google Scholar
• Kinghorn KJ, Castillo-Quan JI, Bartolome F, et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain. 2015;138(Pt 7):1801–1816. doi:10.1093/brain/awv132
   PubMed Web of Science ®Google Scholar
• Lin G, Lee PT, Chen K, et al. Phospholipase PLA2G6, a parkinsonism-associated gene, affects Vps26 and Vps35, retromer function, and ceramide levels, similar to alpha-synuclein gain. Cell Metab. 2018;28(4):605–618 e606. doi:10.1016/j.cmet.2018.05.019
   PubMed Web of Science ®Google Scholar
• Li K, Wang C, Xiong X, et al. Small-cell variant renal oncocytoma: case report on its clinicopathological and genetic characteristics and literature review. Gene. 2020;730:144266. doi:10.1016/j.gene.2019.144266
   PubMed Web of Science ®Google Scholar
• Kuo CL, Chou HY, Chiu YC, et al. Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett. 2020;474:138–150. doi:10.1016/j.canlet.2020.01.019
   PubMed Web of Science ®Google Scholar
• Hu F, Zeng W, Liu X. A gene signature of survival prediction for kidney renal cell carcinoma by multi-omic data analysis. Int J Mol Sci. 2019;20(22):5720. doi:10.3390/ijms20225720
   PubMed Web of Science ®Google Scholar
• Zhang K, Hu S, Wu J, et al. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer. 2009;8(1):11. doi:10.1186/1476-4598-8-11
   PubMed Web of Science ®Google Scholar
• Dawany NB, Dampier WN, Tozeren A. Large-scale integration of microarray data reveals genes and pathways common to multiple cancer types. Int J Cancer. 2011;128(12):2881–2891. doi:10.1002/ijc.25854
   PubMed Web of Science ®Google Scholar
• Grade M, Hummon AB, Camps J, et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer. 2011;128(5):1069–1079. doi:10.1002/ijc.25453
   PubMed Web of Science ®Google Scholar
• Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer. 2011;10(1):15. doi:10.1186/1476-4598-10-15
   PubMed Web of Science ®Google Scholar
• Mazzu YZ, Armenia J, Chakraborty G, et al. A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019;25(14):4480–4492. doi:10.1158/1078-0432.CCR-18-4046
   PubMed Web of Science ®Google Scholar
• Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS. Targeting ribonucleotide reductase M2 and NF-kappaB activation with didox to circumvent tamoxifen resistance in breast cancer. Mol Cancer Ther. 2015;14(11):2411–2421. doi:10.1158/1535-7163.MCT-14-0689
   PubMed Web of Science ®Google Scholar
• Kono N, Inoue T, Yoshida Y, et al. Protection against oxidative stress-induced hepatic injury by intracellular type II platelet-activating factor acetylhydrolase by metabolism of oxidized phospholipids in vivo. J Biol Chem. 2008;283(3):1628–1636. doi:10.1074/jbc.M708622200
   PubMed Web of Science ®Google Scholar
• Eun HS, Cho SY, Lee BS, Seong IO, Kim KH. Profiling cytochrome P450 family 4 gene expression in human hepatocellular carcinoma. Mol Med Rep. 2018;18(6):4865–4876.
   PubMed Web of Science ®Google Scholar
• Johnson N, Maguire S, Morra A, et al. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. Br J Cancer. 2021;124(4):842–854. doi:10.1038/s41416-020-01185-w
   PubMed Web of Science ®Google Scholar
• Lee JE, Hankinson SE, Cho E. Reproductive factors and risk of renal cell cancer: the Nurses’ Health Study. Am J Epidemiol. 2009;169(10):1243–1250. doi:10.1093/aje/kwp030
   PubMed Web of Science ®Google Scholar
• Sass JO, Walter M, Shield JP, et al. 3-hydroxyisobutyrate aciduria and mutations in the ALDH6A1 gene coding for methylmalonate semialdehyde dehydrogenase. J Inherit Metab Dis. 2012;35(3):437–442. doi:10.1007/s10545-011-9381-x
   PubMed Web of Science ®Google Scholar
• Knebel B, Goeddeke S, Poschmann G, et al. Novel insights into the adipokinome of obese and obese/diabetic mouse models. Int J Mol Sci. 2017;18(9):9. doi:10.3390/ijms18091928
   Web of Science ®Google Scholar
• Lu J, Chen Z, Zhao H, et al. ABAT and ALDH6A1, regulated by transcription factor HNF4A, suppress tumorigenic capability in clear cell renal cell carcinoma. J Transl Med. 2020;18(1):101. doi:10.1186/s12967-020-02268-1
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang X, Chen X, Zhang Q, Hong J. Novel immune-related gene signature for risk stratification and prognosis of survival in lower-grade glioma. Front Genet. 2020;11:363. doi:10.3389/fgene.2020.00363
   PubMed Web of Science ®Google Scholar
• Kopecky O, Lukesova S, Vroblova V, et al. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma. Acta Med. 2007;50(3):207–212.
   Google Scholar
• Komohara Y, Hasita H, Ohnishi K, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011;102(7):1424–1431. doi:10.1111/j.1349-7006.2011.01945.x
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Z, Jiang W, et al. Tumor-infiltrating TNFRSF9(+) CD8(+) T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response. Oncoimmunology. 2020;9(1):1838141. doi:10.1080/2162402X.2020.1838141
   PubMed Web of Science ®Google Scholar
• Chevrier S, Levine JH, Zanotelli VRT, et al. An immune atlas of clear cell renal cell carcinoma. Cell. 2017;169(4):736–749 e718. doi:10.1016/j.cell.2017.04.016
   PubMed Web of Science ®Google Scholar
• Groot Kormelink T, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharm Des. 2009;15(16):1868–1878. doi:10.2174/138161209788453284
   PubMed Web of Science ®Google Scholar
• Rajput AB, Turbin DA, Cheang MC, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4444 cases. Breast Cancer Res Treat. 2008;107(2):249–257. doi:10.1007/s10549-007-9546-3
   PubMed Web of Science ®Google Scholar
• Fleischmann A, Schlomm T, Kollermann J, et al. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate. 2009;69(9):976–981. doi:10.1002/pros.20948
   PubMed Web of Science ®Google Scholar